What is the resistance period to crizotinib?

The period of resistance to crizotinib varies based on individual differences and the biological characteristics of the tumor, making it difficult to give an exact time frame. Some clinical studies have shown that most patients develop resistance to crizotinib within 1 to 2 years after starting treatment. Resistance to ALK inhibitors can be divided into primary and secondary resistance. Differential susceptibility to crizotinib has been shown to depend on ALK variants or fusion gene partners. Currently, FISH has become the gold standard for detecting ALK mutations in non-small cell lung cancer.

Drug resistance refers to tumor cells becoming resistant to crizotinib treatment, resulting in the drug no longer being effective or having reduced effectiveness. The occurrence of drug resistance may be related to genetic mutations of tumor cells, changes in signaling pathways, or other mechanisms. Some patients may develop resistance to crizotinib after taking it for a period of time (which may be months to years). However, the time to resistance is unique to each patient and is affected by multiple factors, such as the type of genetic mutation in the tumor, the initial response to treatment, and the patient's overall health.

Doctors usually use regular imaging examinations and tumor marker monitoring to evaluate the efficacy of drugs and detect signs of drug resistance in a timely manner. Once resistance occurs, doctors may consider genetic testing, changing treatment options, combination therapy, individualized treatment and other measures to make adjustments. Resistance does not mean the end of treatment, and there are many other treatment options and strategies that can be considered. Maintaining close communication with doctors and timely discussion of treatment effects and drug resistance are very important for formulating the best treatment plan.

In addition, medical research is constantly striving to explore new treatments and drugs to deal with drug resistance. Patients and physicians can follow the latest research advances and explore possible treatment opportunities on an individual basis.